Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;20(11):817-838.
doi: 10.1038/s41573-021-00283-5. Epub 2021 Aug 25.

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Namit Chaudhary  1 , Drew Weissman  2 , Kathryn A Whitehead  3   4
Affiliations
Review

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Namit Chaudhary et al. Nat Rev Drug Discov. 2021 Nov.

Erratum in

Abstract

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts. Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research is required to optimize mRNA design, intracellular delivery and applications beyond SARS-CoV-2 prophylaxis. In this Review, we describe the technologies that underlie mRNA vaccines, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles. We also overview the pipeline of mRNA vaccines against various infectious disease pathogens and discuss key questions for the future application of this breakthrough vaccine platform.

PubMed Disclaimer

Conflict of interest statement

K.A.W. is an inventor on the following patents related to lipid nanoparticles: US Patent 8,450,298; 8,969,353; 9,556,110; 9,872,911; 9,227,917; 9,439,968; 10,189,802; and 10,844,028. K.A.W. is bound by confidential agreements that prevent her from disclosing related consulting relationships.

Figures

Fig. 1
Fig. 1. IVT mRNA is formulated into lipid nanoparticle vaccines using a cell-free production pipeline.
a | In vitro-transcribed (IVT) mRNA contains five structural elements: a 5′ cap containing 7-methylguanosine linked through a triphosphate bridge to a 2′-O-methylated nucleoside, flanking 5′ and 3′ untranslated regions (UTRs), an open reading frame (ORF) and a poly(A) tail. b | The mRNA is synthetically produced and formulated into vaccines. (1) Once the genome of a pathogen has been sequenced, a sequence for the target antigen is designed and inserted into a plasmid DNA construct. (2) Plasmid DNA is transcribed into mRNA by bacteriophage polymerases in vitro and (3) mRNA transcripts are purified by high performance liquid chromatography (HPLC) to remove contaminants and reactants. (4) Purified mRNA is mixed with lipids in a microfluidic mixer to form lipid nanoparticles. Rapid mixing causes the lipids to encapsulate mRNA instantaneously and precipitate as self-assembled nanoparticles. (5) The nanoparticle solution is dialysed or filtered to remove non-aqueous solvents and any unencapsulated mRNA and (6) the filtered mRNA vaccine solution is stored in sterilized vials.
Fig. 2
Fig. 2. All mRNA delivery vehicles contain cationic or ionizable molecules.
a | Lipid nanoparticles encapsulate mRNA in their core. They consist of four components: ionizable lipids, such as DLin-MC3-DMA, SM-102 (ref.), ALC-0315 (ref.), A18-Iso5-2DC18 (ref.), A6 (ref.) and 306Oi10 (ref.); cholesterol or its variants, β-sitosterol and 20α-hydroxycholesterol; helper lipids, such as DSPC and DOPE; and PEGylated lipids, such as ALC-0159 (ref.) and PEG-DMG. b | Polymers, such as PEI, PBAE, PEG-PAsp(DET) and CART form polymer–mRNA complexes. c | Cationic nanoemulsions contain a squalene core surrounded by an outer shell made of cationic lipid (for example, DOTAP) and surfactants, such as Tween 80 and Span 85. The mRNA adsorbs to the surface via electrostatic binding.
Fig. 3
Fig. 3. Messenger RNA vaccines elicit immunity through transfection of antigen-presenting cells.
(1) Injected mRNA vaccines are endocytosed by antigen-presenting cells. (2) After escaping the endosome and entering the cytosol, mRNA is translated into protein by the ribosome. The translated antigenic protein can stimulate the immune system in several ways. (3) Intracellular antigen is broken down into smaller fragments by the proteasome complex, and the fragments are displayed on the cell surface to cytotoxic T cells by major histocompatibility complex (MHC) class I proteins. (4) Activated cytotoxic T cells kill infected cells by secreting cytolytic molecules, such as perforin and granzyme. (5) Additionally, secreted antigens can be taken up by cells, degraded inside endosomes and presented on the cell surface to helper T cells by MHC class II proteins. (6) Helper T cells facilitate the clearance of circulating pathogens by stimulating B cells to produce neutralizing antibodies, and by activating phagocytes, such as macrophages, through inflammatory cytokines. BCR, B cell receptor; ER, endoplasmic reticulum; TCR, T cell receptor.
Fig. 4
Fig. 4. mRNA vaccines in development protect against an array of common pathogens using disease-specific targeting strategies.
Surface proteins that enable cell entry are commonly used by mRNA vaccines to target viruses, for example, spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), haemagglutinin protein of influenza viruses, membrane and envelope protein (prM-E) of Zika virus, fusion protein of respiratory syncytial virus (RSV) and surface glycoproteins of human immunodeficiency virus (HIV), Ebola virus and rabies virus. Additionally, complex pathogens such as Plasmodium can be targeted using non-surface antigens such as Plasmodium macrophage migratory inhibiting factor (PMIF) or Plasmodium falciparum glutamic-acid-rich protein (PfGARP). Each pathogen poses a unique set of challenges, including high lethality, rapid mutations, immune evasion, new strains and variants–. Depending on the challenges, mRNA vaccines encoding conformation-specific proteins, conserved regions of antigens or monoclonal antibodies can be safely delivered to healthy adults, children, elderly people and pregnant people. VAED, vaccine-associated enhanced disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Syphilis vaccine development: Aligning vaccine design with manufacturing requirements.
    Waugh S, Cameron CE. Waugh S, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2399915. doi: 10.1080/21645515.2024.2399915. Epub 2024 Sep 11. Hum Vaccin Immunother. 2024. PMID: 39262177 Free PMC article.
  • The future of fungi: threats and opportunities.
    Case NT, Berman J, Blehert DS, Cramer RA, Cuomo C, Currie CR, Ene IV, Fisher MC, Fritz-Laylin LK, Gerstein AC, Glass NL, Gow NAR, Gurr SJ, Hittinger CT, Hohl TM, Iliev ID, James TY, Jin H, Klein BS, Kronstad JW, Lorch JM, McGovern V, Mitchell AP, Segre JA, Shapiro RS, Sheppard DC, Sil A, Stajich JE, Stukenbrock EE, Taylor JW, Thompson D, Wright GD, Heitman J, Cowen LE. Case NT, et al. G3 (Bethesda). 2022 Nov 4;12(11):jkac224. doi: 10.1093/g3journal/jkac224. G3 (Bethesda). 2022. PMID: 36179219 Free PMC article.
  • Advances in Engineering Circular RNA Vaccines.
    Zhang Z, Fu Y, Ju X, Zhang F, Zhang P, He M. Zhang Z, et al. Pathogens. 2024 Aug 15;13(8):692. doi: 10.3390/pathogens13080692. Pathogens. 2024. PMID: 39204292 Free PMC article. Review.
  • New-age vaccine adjuvants, their development, and future perspective.
    Verma SK, Mahajan P, Singh NK, Gupta A, Aggarwal R, Rappuoli R, Johri AK. Verma SK, et al. Front Immunol. 2023 Feb 24;14:1043109. doi: 10.3389/fimmu.2023.1043109. eCollection 2023. Front Immunol. 2023. PMID: 36911719 Free PMC article. Review.
  • RNA therapeutics in the clinic.
    Curreri A, Sankholkar D, Mitragotri S, Zhao Z. Curreri A, et al. Bioeng Transl Med. 2022 Jul 6;8(1):e10374. doi: 10.1002/btm2.10374. eCollection 2023 Jan. Bioeng Transl Med. 2022. PMID: 36684099 Free PMC article. Review.
See all "Cited by" articles

References

    1. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 2021;21:83–100. doi: 10.1038/s41577-020-00479-7. - DOI - PMC - PubMed
    1. Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current challenges in vaccinology. Front. Immunol. 2020;11:1181. doi: 10.3389/fimmu.2020.01181. - DOI - PMC - PubMed
    1. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019;28:100766. doi: 10.1016/j.nantod.2019.100766. - DOI
    1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 2014;13:759–780. doi: 10.1038/nrd4278. - DOI - PubMed
    1. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243. - DOI - PMC - PubMed

Publication types